This is a demo store. No orders will be fulfilled.

Epratuzumab (anti-CD22) - Primary antibody, specific to CD22, >95%, high purity, Human IgG4SP, INHIBITOR of CD22 inhibitor, INHIBITOR of CD22 inhibitor

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Human
  • Isotype: Human IgG4SP
  • Conjugation: Unconjugated
In stock
Item Number
Ab175532
Grouped product items
SKU Size
Availability
Price Qty
Ab175532-100μg
100μg
10
$49.90
Ab175532-1mg
1mg
4
$249.90
Ab175532-5mg
5mg
1
$649.90
Ab175532-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,029.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Epratuzumab (anti-CD22) - Primary antibody, specific to CD22, >95%, high purity, Human IgG4SP, INHIBITOR of CD22 inhibitor
Synonyms B cell receptor CD22 precursor antibody | B lymphocyte cell adhesion molecule antibody | B-cell receptor CD22 antibody | B-lymphocyte cell adhesion molecule antibody | BL CAM antibody | BL-CAM antibody | BLCAM antibody | CD 22 antibody | CD22 antibody | C
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host species Human
Specificity CD22
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type INHIBITOR
Mechanism of action INHIBITOR of CD22 inhibitor
Product Description

Epratuzumab (anti-CD22) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab (anti-CD22) is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab (anti-CD22) can induce CD22 phosphorylation. Epratuzumab (anti-CD22) has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases.

Product Properties

Isotype Human IgG4SP
Light Chain Type kappa
SDS-PAGE 27.1 kDa (Light Chain) & 52.3 kDa (Heavy Chain), under reducing conditions; 177.4 kDa, under non-reducing conditions.
Purification Method Protein A purified
Purity >95%
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 205923-57-5

Associated Targets(Human)

CD22 Tclin B-cell receptor CD22 (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Epratuzumab (anti-CD22) (Ab175532) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD22 (red) with Epratuzumab (anti-CD22) (Ab175532). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Epratuzumab (anti-CD22) (Ab175532) - SEC
The purity of Epratuzumab (anti-CD22) (Ab175532) is more than 95% verified by HPLC.

Epratuzumab (anti-CD22) (Ab175532) - ELISA
Immobilized Recombinant Human Siglec-2/CD22 Protein (rp169575) at 1.0 μg/mL can bind Epratuzumab (anti-CD22) (Ab175532) with the EC₅₀ of 207.0 ng/mL.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number Certificate Type Date Item
ZJ24F0303912 Certificate of Analysis Mar 29, 2024 Ab175532
ZJ24F0303911 Certificate of Analysis Mar 29, 2024 Ab175532
ZJ24F0303910 Certificate of Analysis Mar 29, 2024 Ab175532

Alternative Products

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.